Drug Profile
XmAb 2513
Alternative Names: XmAb™2513Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Xencor
- Class Antineoplastics; Immunoglobulins; Monoclonal antibodies
- Mechanism of Action CD30 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hodgkin's disease
- Discontinued T-cell lymphoma
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Hodgkin's-disease in USA (IV, Infusion)
- 10 Jul 2013 XmAb 2513 is still in phase I development for Hodgkin's disease in USA
- 17 Nov 2010 Clinical development of XmAb 2513 is ongoing in USA